Bayer HealthCare to buy Teva Pharma' US animal health business for$145 mn
14 Sep 2012
Bayer HealthCare LLC, a unit of Germany's Bayer AG, today agreed to buy Teva Pharmaceuticals' US animal health business in a $145 million deal.
Tel Aviv, Israel-based Teva will receive an upfront payment of $60 million and $85 million in milestone payments linked to manufacturing and sales targets.
The acquired portfolio will include a strong anti-infectives franchise and will enable Bayer to be present in all major therapeutic areas.
Teva's animal products features a full line of dermatology products sold under the DVM Pharmaceutical brand, including such products as Malaseb, HyLyt, Relief and others.
Teva's companion animal products include a broad line of nutraceuticals encompassing joint and gastro-intestinal products including the Synovi brands and food animal products include a wide range of anti-infectives in addition to parasiticides, anti-inflammatory brands and reproductive hormones.
Bayer, the world's fifth-largest animal health company, said that the acquisition will provide a range of anti-infective solutions for livestock and introducing reproductive hormones to Bayer's product offerings and strengthen its HealthCare companion animal franchise by expanding its portfolio with dermatological, pet wellness and nutraceutical products.
.webp)
